Business Wire

NV-ARMIS

6.8.2024 14:01:31 CEST | Business Wire | Press release

Share
Armis Surpasses $200M ARR, Doubling ARR in Less Than 18 Months

Black Hat Armis, the asset intelligence cybersecurity company, announced today that it has surpassed $200m in annual recurring revenue (ARR), doubling its ARR in less than 18 months and making it one of just a few companies that have achieved this rapid scale, not just in the cybersecurity market, but of any SaaS company worldwide.

Armis’ explosive growth has been driven by its award-winning AI-powered cyber exposure management platform, Armis Centrix™, which has been adopted by the world’s leading organizations, including 35 of the top Fortune 100 companies. Customers like United Airlines, the U.S Postal Service, Ryanair, Mondelez, Reckitt and Flex trust Armis to help them secure their most critical environments. Great demand from national, state, local and Federal entities has led to increased deployment of Armis’ solutions globally. Armis also saw continued momentum across North America, EMEA and APJ which has led Armis to double its ARR in less than 18 months.

“This significant milestone reflects not just our huge financial growth in the last year but shows the unwavering trust that Fortune 100, 200, and 500 companies, large private organizations and healthcare systems, and governments place in us to safeguard their mission critical assets & infrastructure,” said Yevgeny Dibrov, Co-Founder and CEO at Armis. “Our commitment to empowering businesses with robust asset intelligence and security, proactive defense strategies and full risk management has never been stronger. As we continue to expand our impact across industries, this milestone fuels our mission to ensure that every organization can operate confidently in the face of evolving threats.”

Armis’ mission is to protect organizations' entire attack surface by managing cyber risk exposure in real time. Its cloud-based platform Armis Centrix™ and its suite of solutions proactively mitigate all cyber asset risks by identifying every asset, from the ground to the cloud, remediating vulnerabilities and blocking threats to give organizations peace of mind that all critical assets are protected.

Demand for Armis’ award-winning platform Armis Centrix™ continues at a rapid pace. Armis has expanded its capabilities & offerings, with the back to back acquisitions earlier this year of CTCI and Silk Security. Armis Centrix™ product suites now include deeper vulnerability mitigation, prioritization, remediation, risk management and threat intelligence. It has developed a world-class partner first approach and seen expansion with some key partnerships over the last few years such as Accenture, Blackwood, Booz Allen Hamilton, CDI, Fortinet, GuidePoint Security, HCl, KPMG, Nomios, Optiv, Presidio, PWC, Softcat, Source IT Technologies, Telia Cygate, WWT and the AWS and Google Marketplaces.

“Over the past year we have been laser focused on efficient growth, expansion of customer engagement, adoption of our platform Armis Centrix™️, its 5 product suites, and have focused more on expanding our channel partner engagement,” said Jonathan Carr, Chief Financial Officer of Armis. “With our recent acquisitions and expanded capabilities, we continue to see high demand for our platform, its products and are growing well in excess of top public company benchmarks, in addition to our own industry peers.”

“Armis is an integral part of Main Line Health’s cybersecurity program, providing unparalleled visibility into every asset and device within our environment,” said Aaron Weismann, Chief Information Security Officer at Main Line Health. “As a hospital system dedicated to delivering safe, high-quality, equitable and affordable care to treat and cure disease, Armis allows us to focus on what truly matters.”

Industry analysts have recognized Armis’ broad platform offering with Frost & Sullivan awarding Armis two Best Practices awards - Customer Value Leadership for OT Cybersecurity and Technology Innovation Leadership for Global Healthcare Cybersecurity.

Additional industry analyst firm recognition:

The Forrester Wave™: Operational Technology Security Solutions, Q2 2024, “Armis is ideally suited for organizations needing to manage a diverse and sprawling IoT and OT environment.”

Manuel Alborez, Frost & Sullivan Best Practices Research Analyst, “The Armis Centrix™ platform’s overarching distinction is that, through a single pane of glass, it provides a real-time, contextual view of the environment and security posture, monitoring and managing all assets affecting patient care, including IT, OT, IoT, medical devices, enterprise assets, and cloud infrastructure. In addition to this robust visibility, Armis offers cutting-edge threat intelligence and forensic monitoring capabilities.”

Danielle VanZandt, Frost & Sullivan Industry Manager – Commercial & Public Security, “In the face of a sprawling IT, OT, and IoT ecosystem, Armis provides its customers with the centralized management needed to protect their businesses. As organizations shift away from network-centric security, Armis acknowledges the potential vulnerability of any asset type. This enables them to guide security teams in proactive mitigation efforts, safeguarding the robustness of essential business processes across various sectors.”

Chris Ray, GigaOm Analyst, “Armis is a formidable player in the ASM landscape, focusing on asset discovery and management. At its core, the platform utilizes a dual-method approach for asset discovery: integration-based discovery for known assets and deep packet inspection (DPI) of network traffic to unearth everything else.

Additional analyst recognition and awards have been received in the last 12 months and are a testament to Armis’ award-winning Armis Centrix™ platform and approach to customer success:

Recent awards in the last year are as follows:

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806677978/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye